130 related articles for article (PubMed ID: 30671767)
1. Prognostic effects of abnormal DNA damage response protein expression in breast cancer.
Suh KJ; Ryu HS; Lee KH; Kim H; Min A; Kim TY; Yang Y; Lee HB; Moon HG; Han SW; Oh DY; Han W; Park IA; Noh DY; Im SA
Breast Cancer Res Treat; 2019 May; 175(1):117-127. PubMed ID: 30671767
[TBL] [Abstract][Full Text] [Related]
2. DNA damage response markers are differentially expressed in BRCA-mutated breast cancers.
Aleskandarany M; Caracappa D; Nolan CC; Macmillan RD; Ellis IO; Rakha EA; Green AR
Breast Cancer Res Treat; 2015 Feb; 150(1):81-90. PubMed ID: 25690937
[TBL] [Abstract][Full Text] [Related]
3. Increased ID4 expression, accompanied by mutant p53 accumulation and loss of BRCA1/2 proteins in triple-negative breast cancer, adversely affects survival.
Thike AA; Tan PH; Ikeda M; Iqbal J
Histopathology; 2016 Apr; 68(5):702-12. PubMed ID: 26259780
[TBL] [Abstract][Full Text] [Related]
4. The DNA damage signalling kinase ATM is aberrantly reduced or lost in BRCA1/BRCA2-deficient and ER/PR/ERBB2-triple-negative breast cancer.
Tommiska J; Bartkova J; Heinonen M; Hautala L; Kilpivaara O; Eerola H; Aittomäki K; Hofstetter B; Lukas J; von Smitten K; Blomqvist C; Ristimäki A; Heikkilä P; Bartek J; Nevanlinna H
Oncogene; 2008 Apr; 27(17):2501-6. PubMed ID: 17982490
[TBL] [Abstract][Full Text] [Related]
5. Enhanced RAD21 cohesin expression confers poor prognosis in BRCA2 and BRCAX, but not BRCA1 familial breast cancers.
Yan M; Xu H; Waddell N; Shield-Artin K; Haviv I; ; McKay MJ; Fox SB
Breast Cancer Res; 2012 Apr; 14(2):R69. PubMed ID: 22537934
[TBL] [Abstract][Full Text] [Related]
6. BRCA1 alterations with additional defects in DNA damage response genes may confer chemoresistance to BRCA-like breast cancers treated with neoadjuvant chemotherapy.
Takada M; Nagai S; Haruta M; Sugino RP; Tozuka K; Takei H; Ohkubo F; Inoue K; Kurosumi M; Miyazaki M; Sato-Otsubo A; Sato Y; Ogawa S; Kaneko Y
Genes Chromosomes Cancer; 2017 May; 56(5):405-420. PubMed ID: 28124401
[TBL] [Abstract][Full Text] [Related]
7. Nuclear PARP1 expression and its prognostic significance in breast cancer patients.
Mazzotta A; Partipilo G; De Summa S; Giotta F; Simone G; Mangia A
Tumour Biol; 2016 May; 37(5):6143-53. PubMed ID: 26614429
[TBL] [Abstract][Full Text] [Related]
8. MYC overexpression and poor prognosis in sporadic breast cancer with BRCA1 deficiency.
Ren J; Jin F; Yu Z; Zhao L; Wang L; Bai X; Zhao H; Yao W; Mi X; Wang E; Olopade OI; Wei M
Tumour Biol; 2013 Dec; 34(6):3945-58. PubMed ID: 23860775
[TBL] [Abstract][Full Text] [Related]
9. Biological and clinical significance of PARP1 protein expression in breast cancer.
Green AR; Caracappa D; Benhasouna AA; Alshareeda A; Nolan CC; Macmillan RD; Madhusudan S; Ellis IO; Rakha EA
Breast Cancer Res Treat; 2015 Jan; 149(2):353-62. PubMed ID: 25528020
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of tumor-infiltrating lymphocytes and association with prognosis in BRCA-mutated breast cancer.
Sønderstrup IMH; Jensen MB; Ejlertsen B; Eriksen JO; Gerdes AM; Kruse TA; Larsen MJ; Thomassen M; Laenkholm AV
Acta Oncol; 2019 Mar; 58(3):363-370. PubMed ID: 30614364
[TBL] [Abstract][Full Text] [Related]
11. Constitutive expression of γ-H2AX has prognostic relevance in triple negative breast cancer.
Nagelkerke A; van Kuijk SJ; Sweep FC; Nagtegaal ID; Hoogerbrugge N; Martens JW; Timmermans MA; van Laarhoven HW; Bussink J; Span PN
Radiother Oncol; 2011 Oct; 101(1):39-45. PubMed ID: 21840613
[TBL] [Abstract][Full Text] [Related]
12. Prognostic values of negative estrogen or progesterone receptor expression in patients with luminal B HER2-negative breast cancer.
Park C; Park K; Kim J; Sin Y; Park I; Cho H; Yang K; Bae BN; Kim KW; Ahn S; Gwak G
World J Surg Oncol; 2016 Sep; 14(1):244. PubMed ID: 27619909
[TBL] [Abstract][Full Text] [Related]
13. Germline Mutations in Cancer Susceptibility Genes in a Large Series of Unselected Breast Cancer Patients.
Sun J; Meng H; Yao L; Lv M; Bai J; Zhang J; Wang L; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Xie Y
Clin Cancer Res; 2017 Oct; 23(20):6113-6119. PubMed ID: 28724667
[No Abstract] [Full Text] [Related]
14. Numb protein expression correlates with a basal-like phenotype and cancer stem cell markers in primary breast cancer.
Rennstam K; McMichael N; Berglund P; Honeth G; Hegardt C; Rydén L; Luts L; Bendahl PO; Hedenfalk I
Breast Cancer Res Treat; 2010 Jul; 122(2):315-24. PubMed ID: 19795205
[TBL] [Abstract][Full Text] [Related]
15. Effect of germ-line genetic variation on breast cancer survival in a population-based study.
Goode EL; Dunning AM; Kuschel B; Healey CS; Day NE; Ponder BA; Easton DF; Pharoah PP
Cancer Res; 2002 Jun; 62(11):3052-7. PubMed ID: 12036913
[TBL] [Abstract][Full Text] [Related]
16. Expression of BRCA1 and BRCA2 proteins and their correlation with clinical staging in breast cancer.
Hedau S; Batra M; Singh UR; Bharti AC; Ray A; Das BC
J Cancer Res Ther; 2015; 11(1):158-63. PubMed ID: 25879355
[TBL] [Abstract][Full Text] [Related]
17. Simultaneous ATM/BRCA1/RAD51 expression variations associated with prognostic factors in Iranian sporadic breast cancer patients.
Hallajian Z; Mahjoubi F; Nafissi N
Breast Cancer; 2017 Jul; 24(4):624-634. PubMed ID: 28058614
[TBL] [Abstract][Full Text] [Related]
18. Microcephalin is a new novel prognostic indicator in breast cancer associated with BRCA1 inactivation.
Richardson J; Shaaban AM; Kamal M; Alisary R; Walker C; Ellis IO; Speirs V; Green AR; Bell SM
Breast Cancer Res Treat; 2011 Jun; 127(3):639-48. PubMed ID: 20632086
[TBL] [Abstract][Full Text] [Related]
19. Clinical and biological significance of RAD51 expression in breast cancer: a key DNA damage response protein.
Alshareeda AT; Negm OH; Aleskandarany MA; Green AR; Nolan C; TigHhe PJ; Madhusudan S; Ellis IO; Rakha EA
Breast Cancer Res Treat; 2016 Aug; 159(1):41-53. PubMed ID: 27464795
[TBL] [Abstract][Full Text] [Related]
20. The relationship between the roles of BRCA genes in DNA repair and cancer predisposition.
Tutt A; Ashworth A
Trends Mol Med; 2002 Dec; 8(12):571-6. PubMed ID: 12470990
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]